In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.
Perfuze, a medtech has raised €22m. With the infusion, the company will release its catheters to select stroke centres in the US.
Ali, H. , Ghaysaa, H. , Jaafar, W. and Malek, M. (2025) Ischemic Stroke Following Coronary Angiography: A Case Report. Case Reports in Clinical Medicine, 14, 123-129. doi: 10.4236/crcm.2025.143016 .
The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.
The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires ...
Coinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.
Perfuze, an Ireland-based developer of catheter-based aspiration technology for the treatment of acute ischemic stroke, ...
A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...
Perfuze, a leading medical device company dedicated to advancing stroke treatment, today announced that it has received FDA ...
Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly ...
The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.
The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results